Alembic Pharmaceuticals Clears USFDA Inspection at Vadodara Facility with Zero Observations
Alembic Pharmaceuticals Ltd 路 Others (Uncategorized) 路 11 Sept 2026, 5:07 pm
Alembic Pharmaceuticals Clears USFDA Inspection at Vadodara Facility with Zero Observations Alembic Pharmaceuticals has successfully completed an unannounced onsite USFDA bioequivalence inspection at its facility in Vadodara, Gujarat, with zero Form 483 observations. The inspection was conducted from 31st Aug'26 to 10th Sep'26. The clean regulatory outcome eliminates immediate US compliance risks for the bioequivalence site, supporting the company's product development pipeline and regulatory approval timelines for the US market.
Original exchange filing (PDF)
More announcements from Alembic Pharmaceuticals Ltd
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Binimetinib Tablets, 15 mg and 45 mg. 路 15 Nov 2026
- Please find attached herewith the Transcript of Post Results Conference Call held on 4th November, 2026. 路 10 Nov 2026
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). 路 05 Nov 2026
- Please find attached Audio Recording of Investor Call. 路 05 Nov 2026
- Please find attached intimation under Regulation 30(5) of SEBI (LODR) Regulations, 2015. 路 04 Nov 2026
- Please find attached Press Release 路 04 Nov 2026
- Please find attached Investor Presentation for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
- Please find attached Press Release for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
